October 9, 2013

Ligand to Report Third Quarter Results on October 30th

SAN DIEGO-- **Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)** announced today plans to report third quarter 2013 financial results on Wednesday, October 30, 2013. Ligand's President and CEO, John Higgins, Executive Vice President and COO, Matt Foehr and Vice President of Finance and CFO, John Sharp will host the conference call.

Third Quarter Earnings Call

What:	Ligand Pharmaceuticals conference call to discuss financial results and provide general business updates.
When:	Wednesday, October 30, 2013
Time:	6:00 a.m. Pacific time (9:00 a.m. Eastern time)
Webcast:	Conference call and replay accessible at www.ligand.com
Conference Call:	(877) 407-4019, passcode: Ligand
	(201) 689-8337 outside the U.S.
Replay:	(877) 660-6853, passcode: 420734
	(201) 612-7415 outside the U.S.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company that develops and acquires assets it believes will generate royalty revenues and, under its lean corporate cost structure, produce sustainable

profitability. Ligand has a diverse asset portfolio addressing the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis, muscle wasting, dyslipidemia, anemia and osteoporosis. Ligand's Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Lundbeck Inc., Eli Lilly & Co. and Spectrum Pharmaceuticals. Please visit www.captisol.com for more information on Captisol and www.ligand.com for more information on Ligand.

Follow Ligand on Twitter @Ligand_LGND.

Ligand Pharmaceuticals Incorporated
John Higgins, President and CEO
(858) 550-7500
or
LHA
Don Markley
(310) 691-7100
dmarkley@lhai.com

Source: Ligand Pharmaceuticals Incorporated